Alector (NASDAQ:ALEC Get Rating) had its target price reduced by Citigroup from $17.00 to $12.00 in a research report released on Wednesday, Benzinga reports. They currently have a buy rating on the stock. ALEC has been the topic of a number of other research reports. Morgan Stanley dropped ...

AL101 is being developed to elevate progranulin (PGRN) levels with dosing regimens to be optimized for larger indications such as Alzheimers disease Study results in healthy volunteers demonstrated that AL101 increased the level of PGRN, a key regulator of immune activity and lysosomal function in ...

Shares of Alector, Inc. (NASDAQ:ALEC Get Rating) have received an average recommendation of Hold from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating ...

Shares of Alector, Inc. (NASDAQ:ALEC Get Rating) have received a consensus rating of Hold from the eight research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold ...

NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Alector, Inc. (NASDAQ: ALEC) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. ...